Q1 2020

Filed May 14, 2020 · 10-Q · 44 days after period end · 0001558370-20-006569

Q1 2020 · 10-Q

Revenue

$761.00K

— vs Q1 2019

Net Income

-$28.17M

N/M vs Q1 2019

EPS Diluted

-$0.04

N/M vs Q1 2019

Operating Income-$29,764,000N/M

Operating Cash Flow

Same quarter

Metric	Q1 2020	Q1 2019	Q1 2018	Q1 2017
Revenue	$761.00K	$0.00	$8.20M	$2.86M
Net Income	-$28.17M	-$27.41M	-$20.74M	-$21.78M
EPS Diluted	-$0.04	-$0.04	-$0.04	-$0.05

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR